Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation
نویسندگان
چکیده
منابع مشابه
Source of 17-hydroxyprogesterone caproate in clinical trials.
TO THE EDITORS: Rozenberg and colleagues 1 reported that 17-hydroxyprogesterone caproate (17Pc) (500 mg twice/wk) did not significantly increase time to delivery or improve neo-natal outcome when used as maintenance therapy after an episode of preterm labor. We would ask the authors to disclose the source of the drug and to clarify whether there was any testing to assure its quality. This is cr...
متن کاملPrevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate
From Wake Forest University, WinstonSalem, N.C. (P.J.M.); the National Institute of Child Health and Human Development, Bethesda, Md. (M.K., C.Y.S.); the Biostatistics Center, George Washington University, Rockville, Md. (E.T.); Wayne State University, Detroit (M.P.D.); the University of Tennessee, Memphis (B.S.); the University of Chicago, Chicago (A.H.M.); the University of Alabama, Birmingha...
متن کاملPrevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
BACKGROUND Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery. METHODS We conducted a double-blind, placebo-controlled trial involving pregnant women with a documented history of...
متن کاملComparison of intravaginal progesterone gel and intramuscular 17-α-hydroxyprogesterone caproate in luteal phase support
The main objective of this study was to compare the pregnancy rates of intramuscular (IM) 17-α-hydroxyprogesterone caproate (17-HPC) and intravaginal (IV) progesterone gel administration in in vitro fertilization-embryo transfer (IVF-ET) cycles. The IM 17-HPC and IV progesterone groups included 632 (66.4%) and 320 (33.6%) women undergoing the first cycles of IVF-ET treatment, respectively. Mult...
متن کاملOBSTETRICS : Pharmacogenomics of 17 - alpha hydroxyprogesterone caproate for recurrent preterm birth prevention
OBJECTIVE—We hypothesized that genetic variation affects responsiveness to 17-alpha hydroxyprogesterone caproate (17P) for recurrent preterm birth prevention. STUDY DESIGN—Women of European ancestry with ≥1 spontaneous singleton preterm birth at <34 weeks’ gestation who received 17P were recruited prospectively and classified as a 17P responder or nonresponder by the difference in delivery gest...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Obstetrics and Gynecology
سال: 2011
ISSN: 0002-9378
DOI: 10.1016/j.ajog.2011.03.028